Welcome to our dedicated page for SS Innovations International SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SS Innovations International's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SS Innovations International's regulatory disclosures and financial reporting.
SS Innovations International, Inc. insider Sudhir Srivastava, Chairman, CEO and more-than-10% owner, reported a bona fide gift transfer of 10,000 shares of common stock on 2026-08-14. The shares were held indirectly through Sushruta Pvt. Ltd., in which he has a controlling interest. After the gift, indirect holdings reported for this entity total 108,554,261 shares of common stock.
SS Innovations International, Inc. reported record second-quarter 2026 revenue of $13.9 million, up 39.4% from $10.0 million a year earlier, driven mainly by higher SSi Mantra system sales. First-half 2026 revenue was $25.0 million, an increase of 65.6% from $15.1 million in first-half 2025.
The company’s installed base expanded rapidly, with quarterly SSi Mantra installations rising from 23 to 30 and the cumulative installed base increasing from 105 to 224 systems. Quarterly SSi Mantra surgeries grew from 1,042 to 2,528, and cumulative surgeries from 4,657 to 12,272, indicating increased clinical utilization.
Despite strong top-line growth, SS Innovations recorded a net loss of $2.7 million for Q2 2026 versus a $0.3 million loss a year earlier, as operating expenses, including $2.2 million of stock-based compensation and higher R&D and SG&A, outweighed gross profit. For the first half of 2026, net loss was $6.2 million, similar to the prior year. Cash and cash equivalents increased to $22.7 million as of June 30, 2026, supported by a $18.4 million PIPE financing, while total assets reached $97.0 million and stockholders’ equity rose to $53.4 million.
SS Innovations International, Inc. reported strong top-line growth but continued losses for the three and six months ended June 30, 2026. Revenue for the quarter rose to $13.9 million from $10.0 million a year earlier, and six‑month revenue increased to $25.0 million from $15.1 million, driven mainly by higher system sales in India, which represented 93% of six‑month revenue.
Despite higher gross profit of $12.4 million for the first half, operating expenses grew to $18.3 million, including $5.3 million of stock‑based compensation and $3.4 million of research and development. The company posted a six‑month net loss of $6.2 million and total comprehensive loss of $8.2 million.
Liquidity improved after a March 2026 private placement that raised $18.4 million, contributing to cash, cash equivalents and restricted cash of $22.7 million at June 30, 2026 and a working capital surplus of $39.6 million. However, management states that existing cash and operating income are not expected to fund operations for the next 12 months, and explicitly notes substantial doubt about the company’s ability to continue as a going concern without additional financing or improved performance.
SS Innovations International, Inc. reports that CFO Sarah Romano holds options to purchase 750,000 shares of common stock, granted on August 3, 2026 at an exercise price of $3.95 per share and expiring on August 3, 2031.
The options vest 250,000 shares on August 3, 2027, then in 23 monthly installments of 20,833 shares and a final 20,841-share installment, subject to continued employment and immediate full vesting upon a qualifying Change in Control.
SS Innovations International, Inc. reported that its SSi Mantra surgical robotic system will be showcased at the 2026 Society of Robotic Surgery Annual Meeting in Hollywood, Florida on July 23-26, 2026. The system will be on display, featured in multiple breakout sessions, and used in a livestreamed kidney telesurgery partial nephrectomy between Gurugram and New Delhi, India. Chairman and CEO Dr. Sudhir Srivastava is scheduled to speak and participate in several sessions at the event.
As of July 6, 2026, cumulative multi-specialty procedures completed with the SSi Mantra totaled 12,375, including 653 cardiac procedures, 178 telesurgeries, and 225 pediatric surgeries. Approximately 2,100 physicians have been trained on the system, which has been used in over 170 different types of procedures.
SS Innovations International, Inc. appointed Sarah M. Romano as Chief Financial Officer, effective August 3, 2026, under a three-year employment agreement. The agreement provides an annual base salary of $440,000 plus eligibility for an annual performance-based cash bonus.
Romano will receive options under the 2026 Incentive Stock Plan to purchase 750,000 shares of common stock, vesting as to 250,000 shares on the first anniversary and then in 23 monthly installments of 20,833 shares and a final installment of 20,841 shares, subject to continued employment. The contract includes customary confidentiality, proprietary rights, non-competition and non-solicitation covenants and an indemnification agreement. Romano brings more than two decades of financial leadership experience in medical technology and life sciences companies and has helped raise over $100 million through public and private financings.
SS Innovations International, Inc. reported that its subsidiary, the SS International Centre for Robotics Surgery (SSICRS), has graduated its first class from a specialized training course in robotic-assisted cardiac surgery using the Company’s SSi Mantra surgical robotic system at its headquarters in Gurugram, India.
The inaugural program combines classroom instruction with hands-on lab work on the SSi Mantra platform, aiming to train surgeons and other healthcare professionals in advanced robotic techniques. SSICRS plans ongoing condensed five-day courses across multiple specialties, including cardiac, urologic, gynecologic, thoracic, colorectal, gastrointestinal, and general surgery, supported by modern lecture halls, state-of-the-art labs, tele-proctoring, and complementary online modules.
SS Innovations International, Inc. reported that it was named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards, an honor given each year to a single surgical robotics company. Management noted that SS Innovations surpassed nine other established finalists, highlighting industry recognition for its SSi Mantra surgical robotic system.
The Company also shared operational milestones. As of June 22, 2026, the SSi Mantra system had been used in 11,719 multi-specialty procedures, including 612 cardiac procedures, 175 telesurgeries and 212 pediatric surgeries, and approximately 2,100 physicians had been trained on the platform across more than 170 procedure types. The SSi Mantra had received regulatory approval in 14 countries, supporting the Company’s goal of making robotic surgery more accessible globally.
SS Innovations International, Inc. entered an ATM Sales Agreement with Virtu Americas LLC to sell up to $50 million of its common stock through an at-the-market offering program. Virtu will act as exclusive sales agent or principal and receive up to 3.0% of gross proceeds from any shares sold.
The sales will be made under the company’s effective Form S-3 shelf registration statement, supported by a new prospectus supplement filed the same day. The agreement includes customary representations, covenants, indemnification and allows either party to terminate in accordance with its terms.
SS Innovations International, Inc. is offering up to $50,000,000 of common stock in an at-the-market (ATM) program under a Sales Agreement with Virtu Americas LLC dated June 18, 2026.
Sales may occur from time to time on Nasdaq or other U.S. trading venues at market prices; Virtu may act as agent or principal and is entitled to a commission of up to 3.0% of gross proceeds. The number of shares outstanding used for this offering calculation was 200,131,535 shares as of June 17, 2026. Net proceeds, if any, are intended for working capital and general corporate purposes, including global marketing, clinical trials and manufacturing capacity expansion.